Answers are grounded in this paper and cite their sources.
This JAMA Insights Clinical Update discusses management options for women with vulvovaginal atrophy, focusing on the systemic safety of estrogen-based therapies and shared decision-making based on preference, cost, and adverse effect profile.
No takes yet. Share an insight, caveat, or question.
Carolyn Crandall (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: